SCM
CBAY

Soleus Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Soleus Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-373,000
Closed -$4.08M – 122
2023
Q2 		$4.08M Buy
+373,000
New +$3.47M 0.45% 55

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Soleus Capital Management's CBAY Position: Q3 2023 in Review

Soleus Capital Management sold out of Cymabay Therapeutics (CBAY) in Q3 2023, closing a stake of 373,000 shares — an estimated $4.08M sold.

Soleus Capital Management first reported a position in CBAY in Q2 2023 and held it in 1 quarter. The position peaked at $4.08M in Q2 2023. 189 funds tracked by Wall St. Rank hold CBAY as of Q3 2023.

  • Soleus Capital Management reported no remaining Cymabay Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Soleus Capital Management sold 373,000 Cymabay Therapeutics shares in Q3 2023, an estimated $4.08M.
  • Soleus Capital Management first reported a position in Cymabay Therapeutics in Q2 2023 and held it in 1 quarter.
  • Soleus Capital Management's Cymabay Therapeutics position peaked at $4.08M in Q2 2023.
  • 189 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2023.

Based on Soleus Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.